Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus.~* Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis.~* Able to tolerate topical corticosteroids for atopic dermatitis lesions.~Exclusion Criteria:~* Prior exposure to any Janus kinase (JAK) inhibitor.~* Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study.~* Requirement of prohibited medications during the study.~* Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
- Arm B (Type: EXPERIMENTAL): Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
- Arm C (Type: EXPERIMENTAL): Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
- Arm D (Type: EXPERIMENTAL): Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.

Based on this trial design, predict the completion outcome and termination type (if applicable).